At a glance
ClinicalIndex Comparison RecordN/ACompleted· 11,296 enrolled
Drug / intervention
Olodaterol/Tiotropium Bromide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Role of Inhaler Device in the Treatment Persistence With Dual Bronchodilators in Patients With COPD
In Brief
An observational study evaluating Olodaterol/Tiotropium Bromide and Umeclidinium/ Vilanterol for Pulmonary Disease, Chronic Obstructive. Completed, enrolled 11,296 participants across 1 site.
Detailed Summary
To compare the persistence in using two different medications from the same drug class (LAMA/LABA FDC) which are delivered through different devices, a dry-powder inhalers (DPI) and Soft Mist Inhalers (SMI).
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Disease, Chronic Obstructive
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
2020202120222023202420252026
First PostedJun 2019
Enrollment StartJun 2019
Primary CompletionJun 2019
TodayJul 2026
First PostedJun 7, 2019
Enrollment StartJun 10, 2019
Primary CompletionJun 11, 2019
TodayJul 2, 2026
Enrollment to primary: 1 daysPosted 7.1 years ago
Interventions
Olodaterol/Tiotropium Bromidedrug
(Stiolto®) delivered via Respimat inhaler
Umeclidinium/ Vilanteroldrug
(Anoro®) delivered via Ellipta Inhaler